<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195780</url>
  </required_header>
  <id_info>
    <org_study_id>M03-647</org_study_id>
    <nct_id>NCT00195780</nct_id>
  </id_info>
  <brief_title>A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents</brief_title>
  <official_title>An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the long-term safety profile of the Investigational
      Medication Depakote ER in the treatment of Bipolar I Disorder, manic or mixed episode, in
      children and adolescents ages 10-17.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Y-MRS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-S</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-GAS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDRS-R</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGSQ</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>responders</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remitters</measure>
  </secondary_outcome>
  <enrollment type="Actual">227</enrollment>
  <condition>Bipolar I Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex Sodium (Depakote ER)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is between 10 and 17 years of age, inclusive, on Day 1 and weighs at least 60
             lbs (27 kg).

          -  Subject has a current psychiatric diagnosis of bipolar I disorder, manic or mixed
             episode, based on the K-SAD-PL interview and DSM-IV-TR criteria.

          -  Subject is an outpatient in a manic or mixed episode with a YMRS score of greater than
             or equal to 16 during Screening and at Day 1.

        Exclusion Criteria:

          -  Has an Axis I disorder other than Attention Deficit Hyperactivity Disorder (ADHD),
             Obsessive Compulsive Disorder (OCD), Oppositional Defiant Disorder (ODD), Conduct
             Disorder (CD), Panic Disorder, Enuresis, Encopresis, Parasomnias, Agoraphobia,
             Specific Phobia, Social Phobia or Separation Anxiety Disorder; or subject has an Axis
             II disorder that would interfere with the subject's ability to comply with study
             procedures or confound interpretation of the study results. Subject meets DSM-IV-TR
             criteria for substance abuse within the month prior to Screening, or meets the
             criteria for substance dependence within the three months prior to Screening, or
             exhibits signs of drug or alcohol intoxication or withdrawal at Day 1.

          -  Is expected to require hospitalization for the current manic or mixed episode.

          -  Is violent, homicidal, or suicidal such that, in the opinion of the investigator, the
             subject is at significant imminent risk of hurting self or others.

          -  Has a history of a chronic or acute medical disorder that, in the opinion of the
             investigator, would preclude compliance with the protocol, or confound interpretation
             of the study results.

          -  Has a history of, or is suspected of having a seizure disorder.

          -  Has any central nervous system (CNS) neoplasm, CNS infection, demyelinating disease,
             degenerative neurological disease, or any progressive CNS disease.

          -  Has Platelet count less than or equal to 100,000/ÂµL

          -  Has blood chemistry ALT/AST value(s) greater than or equal to 2 times upper limit of
             normal at screening.

          -  Is taking a protocol allowed medication for ADHD that has not been stable for at least
             3 months prior to Day 1, or that, in the investigator's opinion, may be exacerbating
             mood symptoms.

          -  Requires anticoagulant drug therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Medical Information</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PCSD Feighner Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCSD Feighner Research</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kolin Research Group</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northlake Medical Research Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain West Clinical Trials</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capstone Clinical Research</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinco</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cientifica Inc.</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brentwood Research Institute</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acadia Hospital</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04402-0422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmasite Research</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Neuropsychiatry, PA</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odyssey Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Behavioral Clinical Research, INC.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Professional Services</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rakesh Ranjan, M.D. &amp; Associates, Inc.</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Specialists</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004-1604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UTHSC, Sept. of Psychiatry, College of Medicine</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InSite Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R/D Clinical Research</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>June 29, 2007</last_update_submitted>
  <last_update_submitted_qc>June 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2007</last_update_posted>
  <keyword>Bipolar I Disorder</keyword>
  <keyword>Depakote</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

